ReviewAdvances in experimental medicine and biology2026
Genomics in Health and Biomedicine.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Opportunities and Risks of Technology Convergence in Precision Health.Blockchain in healthcare today · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomic information is rapidly becoming a cornerstone of personalized medicine, offering transformative potential for clinical practice. This chapter explores the critical role of genomics in enabling earlier diagnosis, precise treatment, risk prediction, and preventive healthcare strategies. Advances in sequencing technologies, data integration, and bioinformatics allow for tailored healthcare solutions based on an individual's genetic profile, combined with clinical, lifestyle, and environmental data. Integration with electronic health records, mHealth technologies, and artificial intelligence further enhances clinical decision-making. The chapter highlights current applications of genomic medicine in oncology, rare diseases, and pharmacogenomics and the growing relevance of polygenic risk scores in managing common chronic diseases. It also discusses the need for harmonized data governance, infrastructure development, professional training, and public engagement to ensure equitable and effective implementation. These developments are situated within the broader landscape of national and international initiatives-including ICPerMed, 1Million Genomes, and the Genome of Europe project-that aim to foster collaboration, standardization, and equitable access to genomic healthcare across populations. Clinical areas where genomics has already demonstrated substantial value are discussed while identifying key challenges and priorities for advancing the future of personalized medicine.
Indexed as
Identifiers
42071152What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.